…50mg in adult levodopa treated Parkinson’s Disease (PD) patients without motor complications. In the EPSILON study, opicapone 50 mg was found to be statistically significantly superior versus placebo in its…
Content Section:
News Posts
…biopharma business of Merck Results from a post hoc analysis (EP1573) evaluating five-year disease stability demonstrated sustained efficacy of cladribine tablets on disability progression, as measured by the Expanded Disability…
Content Section:
News Posts
TECFIDERA consistently maintained low levels of disease activity with no increased risk in adverse events over a decade of treatment Latest interim data from Phase 3 EVOLVE-MS-1 trial show Biogen…
Content Section:
News Posts
Eisai has submitted a Marketing Authorisation Application (MAA) for lecanemab, an investigational anti-amyloid beta (Aβ) protofibril antibody, for the treatment of early Alzheimer’s disease (AD) (mild cognitive impairment due to…
Content Section:
News Posts
…with nonsense mutation Duchenne muscular dystrophy aged 2 years and older who can walk. Duchenne is a severe progressive disease that leads to rapidly worsening muscle function with children often…
Content Section:
News Posts
…Scottish Medicines Consortia are due to review their funding decision in March 2020. “Although disease-modifying therapies have been shown to be effective in reducing relapse rates and disease progression in…
Content Section:
News Posts
…in the US for the treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive, which represents 80% of people living with the disease.1-5 The…
Content Section:
News Posts
…that affect our brain from working normally. Such illnesses are Alzheimer’s disease, Lewy body disease and other conditions affecting different parts of the brain. Dementia can affect people’s memory or…
Content Section:
Event News
…and engaged through virtual platforms. The course was sectioned into palliative care principles across four core neurological conditions: dementia, Parkinson’s, multiple sclerosis (MS) and motor neurone disease (MND). Each condition…
Content Section:
Conference Reports